Corpus Intelligence IC Memo — NORTHERN CALIFORNIA REHAB HOSPITAL 2026-04-26 09:37 UTC
IC Memo — NORTHERN CALIFORNIA REHAB HOSPITAL
Investment Committee Memorandum | CA | 56 beds | Grade D | EBITDA uplift $3.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

NORTHERN CALIFORNIA REHAB HOSPITAL

CCN 052047 | SHASTA, CA | 56 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

NORTHERN CALIFORNIA REHAB HOSPITAL is a 56-bed community hospital in SHASTA, CA with $43.3M in net patient revenue and a 10.0% operating margin. The hospital serves a payer mix of 59.1% Medicare, 0.0% Medicaid, and 40.9% commercial.

Thesis: Turnaround. Our ML models identify $3.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 10.0% to 17.4% (+736bps).

Net Revenue HCRIS$43.3M
Current EBITDA COMPUTED$4.3M
Operating Margin COMPUTED10.0%
Occupancy HCRIS60.4%
Revenue / Bed COMPUTED$773K
Net-to-Gross HCRIS10.9%
Distress Probability MLnan%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
114
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of 10.0% places it above the state median. Among 114 size-comparable peers (28-112 beds), the median margin is -5.9%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (28-112), prioritizing same-state peers. 114 hospitals in the comp set.

HospitalStateBedsRevenueMargin
NORTHERN CALIFORNIA REHAB HOSP (Target)CA56$43.3M10.0%
RANCHO LOS AMIGOS NATL.REHAB.CCA83$512.6M41.9%
USC NORRIS CANCER HOSPITALCA60$468.7M19.1%
KFH - FREMONTCA100$296.2M-6.6%
MERCY HOSPITAL OF FOLSOMCA106$287.8M17.0%
MARSHALL HOSPITALCA111$286.0M-5.9%
LLUMC MURRIETACA111$276.7M-20.3%
ADVENTIST HEALTH SONORACA84$274.3M-7.4%
CPMC-R.K. DAVIES MEDICAL CENTECA105$243.7M24.6%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $3.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$909K+210bp18mo
Cost to Collect4.5%2.5%$866K+200bp12mo
Denial Rate Reduction12.0%6.5%$857K+198bp12mo
A/R Days Reduction5200.0%3800.0%$527K+122bp9mo
Clean Claim Rate88.0%96.0%$28K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$909K
Cost to Collect
$866K
Denial Rate Reduction
$857K
A/R Days Reduction
$527K
Clean Claim Rate
$28K
Total EBITDA Uplift$3.2M
Current EBITDA$4.3M
+ RCM Uplift+$3.2M
Pro Forma EBITDA$7.5M
Current Margin10.0%
Pro Forma Margin17.4%
WC Released (1x)$1.7M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$6.7M$60.5M9.06x55.4%
Base (11x exit)10.0x11.0x$6.7M$68.7M10.29x59.4%
Bull Case9.0x11.0x$6.0M$81.4M13.55x68.4%
Bull (12x exit)9.0x12.0x$6.0M$90.6M15.07x72.0%
Bear Case11.0x10.0x$7.3M$42.4M5.77x42.0%
Bear (11x exit)11.0x11.0x$7.3M$49.0M6.67x46.2%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumHeavy Medicare dependenceMedicare comprises 59.1% of days; rate updates may lag inflation. Mitigant: CDI/CMI lever directly increases Medicare reimbursement
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 114 hospitals with 28-112 beds
  • Same-state prioritization (n=115)
  • Comp margins: P25=-21.2% / P50=-5.9% / P75=1.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.